methyl 3-amino-6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate | 35212-91-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: methyl 3-amino-6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate
• 英文别名: 2-Carbomethoxy-3-amino-6-trifluoromethylbenzo[b]thiophene；Methyl 3-amino-6-(trifluoromethyl)-1-benzothiophene-2-carboxylate
• CAS: 35212-91-0
• 化学式: C₁₁H₈F₃NO₂S
• 分子量: 275.251
• InChiKey: AGWDAEJQKIRCEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  365.9±37.0 °C(Predicted)
• 密度：
  1.474±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 3-amino-6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate 以87的产率得到1-(6-(trifluoromethyl)-benzo[b]thien-3-yl)-piperazine
  参考文献：
  名称：

  2003229066A1

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氰基-3-硝基三氟甲基苯 、 巯基乙酸甲酯 在 lithium hydroxide 、 水 作用下， 以 N-甲基吡咯烷酮 、 水 为溶剂， 反应 3.97h， 以84.7%的产率得到methyl 3-amino-6-(trifluoromethyl)benzo[b]thiophene-2-carboxylate
  参考文献：
  名称：

  Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands

  摘要：

  该发明涉及对多巴胺D3受体显示选择性结合的杂环取代脲衍生物。另一方面，该发明涉及一种用于治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，患者需要接受此类治疗，包括向受试者施用所述化合物的治疗有效量以缓解此类疾病。可以用这些化合物治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔·德·拉·图雷特综合征和亨廷顿病）、痴呆、焦虑障碍、睡眠障碍、昼夜节律障碍和情绪障碍。该发明还涉及所述化合物的制备过程以及将其作为多巴胺D3受体成像剂的方法。

  公开号：

  US20030229066A1

文献信息

• Anti-epileptogenic agents
  申请人：Queen's University at Kingston

  公开号：US06306909B1

  公开（公告）日：2001-10-23

  Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and epileptogenesis. Methods for preparing the compounds of the invention are also described.

  本发明揭示了用于抑制癫痫等抽搐性疾病的方法和化合物。该发明的方法和化合物可以抑制或预防发作和癫痫发生。同时还描述了制备该发明化合物的方法。
• Microwave-assisted synthesis of 3-aminobenzo[b]thiophene scaffolds for the preparation of kinase inhibitors
  作者：Mark C. Bagley、Jessica E. Dwyer、Maria D. Beltran Molina、Alexander W. Rand、Hayley L. Rand、Nicholas C. O. Tomkinson

  DOI：10.1039/c5ob00819k

  日期：——

  at 130 °C provides rapid access to 3-aminobenzo[b]thiophenes in 58–96% yield. This transformation has been applied in the synthesis of the thieno[2,3-b]pyridine core motif of LIMK1 inhibitors, the benzo[4,5]thieno[3,2-e][1,4]diazepin-5(2H)-one scaffold of MK2 inhibitors and a benzo[4,5]thieno[3,2-d]pyrimidin-4-one inhibitor of the PIM kinases.

  在三乙胺存在下，在130°C的条件下，在三乙胺的存在下对2-卤代苄腈和巯基乙酸甲酯进行微波辐射，可以快速获得3-氨基苯并[ b ]噻吩，产率58-96％。此转化已应用于LIMK1抑制剂噻吩并[2,3- b ]吡啶核心基序，苯并[4,5]噻吩并[3,2- e ] [1,4] diazepin-5（2）的合成中H）-一个MK2抑制剂的支架和PIM激酶的苯并[4,5]噻吩并[3,2 - d ]嘧啶-4-酮抑制剂。
• [EN] HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS<br/>[FR] DERIVES DE CARBONYLE SUBSTITUES HETEROCYCLIQUES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR DE LA DOPAMINE D3
  申请人：AVENTIS PHARMA INC

  公开号：WO2002066446A1

  公开（公告）日：2002-08-29

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson s Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington s Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D¿3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地结合多巴胺D3受体。另一方面，本发明涉及一种用于治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的过程，以及将所述化合物用作多巴胺D3受体成像剂的方法。
• Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20050107389A1

  公开（公告）日：2005-05-19

  The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代酰胺衍生物，其表现出对多巴胺D3受体的选择性结合。在另一个方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备上述化合物的过程，以及将这些化合物作为多巴胺D3受体成像剂的方法。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor
  申请人：Aventis Pharmaceutical Inc.

  公开号：US20040220173A1

  公开（公告）日：2004-11-04

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，该衍生物显示出对多巴胺D3受体的选择性结合。在另一个方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者给予所述化合物的治疗有效量以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备上述化合物的过程以及将其作为多巴胺D3受体成像剂的方法。